Divya Chandradhara

Divya Chandradhara

Active Director Director DIN 07526159
DIN 07526159 First appointment Jul 2016 Primary industry Research & Development
Unlock full profile Investments · shareholding · contact details
Current companies 4 active board seats
Past companies 4 historical roles
Total affiliations 8 Since Jul 2016
Shareholding value •••• Premium profile

About Divya Chandradhara

Data last updated:

Divya Chandradhara is a Director at Bioagile Therapeutics Private Limited (since 2016), Director at Biomantra International Private Limited (since 2025) and Director at Kempville Beverages Private Limited (since 2025), and holds 1 more current directorship. The companies operate in Research & Development, Agriculture and Chemicals. The largest current company by reported revenue is Bioagile Therapeutics Private Limited at ₹1.21 Cr (FY 2024). Earlier, Divya Chandradhara was a Director at Veles Therapeutics Private Limited (2022–2023) and Director at Biovein Innovative Solutions Private Limited (2018–2019) and 2 more.

DIN 07526159
Primary Designation Director
Industry Research & Development
First Appointment 11 Jul 2016
Oldest Company Age 10 yrs
Largest company Bioagile Therapeutics Private Limited · ₹1.21 Cr (FY 2024)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director11 Jul 20162016₹1.21 Cr (FY 2024)Active
Director01 Aug 20252025Active
Kempville Beverages Private Limited U10791KA2025PTC202812
Director14 May 20252025Active
Nexvaxi Therapeutics Private Limited U24110KA2021PTC143889
Director08 Feb 20212021Active

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Veles Therapeutics Private Limited U73100KA2022PTC163522
Director07 Jul 20222022Active
Director19 Dec 20182018₹32.2 Lakh (FY 2024)Active
Adso Naturals Private Limited U15115KA2018PTC109657
Director18 Jan 20182018₹3.03 Cr (FY 2024)Active
Eirs Research Labs Private Limited U74999KA2020PTC140694
Director05 Nov 20202020Strike Off

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Nexvaxi Therapeutics Private Limited
Bioagile Therapeutics Private Limited
Eirs Research Labs Private Limited
Biomantra International Private Limited
Premium access

Shareholding and investment profile for Divya Chandradhara

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Divya Chandradhara

Divya Chandradhara currently holds 4 directorships: Bioagile Therapeutics Private Limited (Director, since 11 Jul 2016, revenue ₹1.21 Cr (FY 2024)); Biomantra International Private Limited (Director, since 01 Aug 2025); Kempville Beverages Private Limited (Director, since 14 May 2025); Nexvaxi Therapeutics Private Limited (Director, since 08 Feb 2021).

Divya Chandradhara was first appointed on 11 Jul 2016 as Director at Bioagile Therapeutics Private Limited. The most recent appointment on record is 01 Aug 2025 at Biomantra International Private Limited.

Divya Chandradhara held 4 earlier board appointments: Veles Therapeutics Private Limited (Director, 07 Jul 2022 to 25 Aug 2023); Biovein Innovative Solutions Private Limited (Director, 19 Dec 2018 to 20 Nov 2019); Adso Naturals Private Limited (Director, 18 Jan 2018 to 11 Sep 2020); Eirs Research Labs Private Limited (Director, from 05 Nov 2020).

The current boards of Divya Chandradhara's companies include Shivanna Renukaprabhe (Bioagile Therapeutics Private Limited), Mahesh Gopalakrishna Shetty (Biomantra International Private Limited), Ujjal Ghosh (Kempville Beverages Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available